GENE ONLINE|News &
Opinion
Blog

2021-10-28| Policy

Big Pharma and Non-Profits Join NIH, FDA in New Rare Diseases Drive

by Joy Lin
Share To
The US National Institutes of Health (NIH) and FDA have joined forces with 10 pharmas and five non-profits to boost the number of approved gene therapies for rare diseases.

The new partnership, called the Bespoke Gene Therapy Consortium (BGTC), will be part of the NIH Accelerating Medicines Program (AMP) and managed by the Foundation for the National Institutes of Health (FNIH). The NIH and private partners will contribute around $76 million in funding for the program over a five-year period. The participating NIH institutes and centers are expected to chip in over half the funds, at $39.5 million.

“Most rare diseases are caused by a defect in a single gene that could potentially be targeted with a customized or ‘bespoke’ therapy that corrects or replaces the defective gene,” said NIH Director Francis S. Collins, M.D., Ph.D.

GO Prime with only $1.49 now

LATEST
BIODND – An AI-Powered Database That Breaks New Ground in Life Science Business Development
2023-11-29
GeneOnline’s Weekly News Highlights: Nov 20-Nov 24
2023-11-27
SK Bioscience and Hilleman Laboratories Join Forces for Ebola Vaccine Development
2023-11-23
BeiGene to Expand Oncology Pipeline Through ENSEM Therapeutics Partnership
2023-11-23
Advancing the Frontiers of Cell and Gene Therapy – An Interview with Dr. Shin Kawamata
2023-11-21
Astellas and Pfizer’s Drug Receives FDA Approval as Treatment for High-Risk Prostate Cancer Recurrence
2023-11-21
GeneOnline’s Weekly News Highlights: Nov 13-Nov 17
2023-11-20
EVENT
2023-11-30
2023 Healthcare+ EXPO・Taiwan
Taipei , Taiwan
Scroll to Top